Anti-CD3-anti-SCLC bispecific monoclonal antibody
Alternative Names: Anti-CD3-anti-SCLC monoclonal antibody; OKT3-LU246 bispecific monoclonal antibodyLatest Information Update: 02 Jul 1998
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Small cell lung cancer
Most Recent Events
- 02 Jul 1998 Profile reviewed
- 02 Jul 1998 No-Development-Reported for Small cell lung cancer in Japan (Unknown route)
- 28 May 1996 Preclinical development for Small cell lung cancer in Japan (Unknown route)